Aumolertinib challenge as an optional treatment in advanced non small‑cell lung cancer after osimertinib failure with epidermal growth factor receptor‑sensitive mutation: A case series

Ding,Xinjing; Ding,Jianghua; Leng,Zhaohui; Song,Yun

doi:10.3892/ol.2022.13520

Aumolertinib challenge as an optional treatment in advanced non small‑cell lung cancer after osimertinib failure with epidermal growth factor receptor‑sensitive mutation: A case series

Authors:
- Xinjing Ding
- Jianghua Ding
- Zhaohui Leng
- Yun Song
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Hematology and Oncology, Jiujiang University Affiliated Hospital, Jiujiang, Jiangxi 332000, P.R. China, Department of Hematology and Oncology, Jiujiang University Affiliated Hospital, Jiujiang, Jiangxi 332000, P.R. China
Published online on: September 22, 2022 https://doi.org/10.3892/ol.2022.13520
Article Number: 400
Copyright: © Ding et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osimertinib, as the first third‑generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has been recommended universally as the priority front‑line therapeutic for advanced non‑small cell lung cancer (NSCLC) carrying EGFR‑sensitive mutations. However, patients inevitably acquire drug resistance to osimertinib. Aumolertinib is the second third‑generation EGFR‑TKI and has been similarly approved as a first‑line treatment agent. The present study reports the cases of 3 patients who were challenged with aumolertinib after osimertinib failure. All 3 patients achieved a partial remission. The progression‑free survival periods following aumolertinib were 10.0, 11 and 9.0 months (at the time of writing the study). Although the patient in case 2 succumbed to an intracerebral hemorrhage due to hypertension, aumolertinib remained effective as a treatment in cases 1 and 3. The present case series suggests the use of aumolertinib challenge as an optional treatment for patients with metastatic NSCLC harboring EGFR‑sensitive mutations after osimertinib failure. The therapeutic strategy of switching from osimertinib to aumolertinib is worth exploring further in the near future.

View Figures

View References

1	He J, Huang Z, Han L, Gong Y and Xie C: Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (Review). Int J Oncol. 59:902021. View Article : Google Scholar : PubMed/NCBI
2	Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, et al: Osimertinib in Untreated EGFR-Mutated Advanced non-small-cell lung cancer. N Engl J Med. 378:113–125. 2018. View Article : Google Scholar : PubMed/NCBI
3	Schmid S, Li JJN and Leighl NB: Mechanisms of osimertinib resistance and emerging treatment options. Lung Cancer. 147:123–129. 2020. View Article : Google Scholar : PubMed/NCBI
4	Lu S, Dong X, Jian H, Chen J, Chen G, Sun Y, Ji Y, Wang Z, Shi J, Lu J, et al: AENEAS: A randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastaticnon-small-cell lung cancer with EGFR Exon 19 Deletion or L858R Mutations. J Clin Oncol. Sep 20–2022.(Epub ahead of print).
5	Deeks ED: Furmonertinib: First Approval. Drugs. 81:1775–1780. 2021. View Article : Google Scholar : PubMed/NCBI
6	Jian H, Wang K, Cheng Y, Ding L, Wang Y, Shi Z, Zhang L, Wang Y and Lu S: Phase I trial of a third generation EGFR mutant-selective inhibitor (D-0316) in patients with advanced non-small cell lung cancer. Oncologist. 27:163–e213. 2022. View Article : Google Scholar : PubMed/NCBI
7	Lv W, Cheng H, Shao D, Wei Y, Zhu W, Wu K, Jiang W, Hu L, Sha Z, Zhong B and Pei X: Treatment patterns and survival of patients with advanced non-small cell lung cancer guided by comprehensive genomic profiling: Real-World single-institute study in China. Front Oncol. 11:6307172021. View Article : Google Scholar : PubMed/NCBI
8	Chang Y, Liu S, Jiang Y, Hua L and Wen L: Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, cis-G796s/cis-C797s by osimertinib, brigatinib, and bevacizumab combination therapy: A case report. Respir Med Case Rep. 36:1015822022.PubMed/NCBI
9	Wang Y, Han R, Zhu M, He T and He Y: Case report: Durable response to the combination of brigatinib and cetuximab plus icotinib in a NSCLC patient harboring EGFR L858R-T790M-cis-G796S and L718Q resistance mutations following progression with osimertinib. Front Oncol. 12:8753132022. View Article : Google Scholar : PubMed/NCBI
10	Yang F, Markovic SN, Molina JR, Halfdanarson TR, Pagliaro LC, Chintakuntlawar AV, Li R, Wei J, Wang L, Liu B, et al: Association of sex, age, and eastern cooperative oncology group performance status with survival benefit of cancer immunotherapy in randomized clinical trials: A systematic review and meta-analysis. JAMA Netw Open. 3:e20125342020. View Article : Google Scholar : PubMed/NCBI
11	Chansky K, Detterbeck FC, Nicholson AG, Rusch VW, Vallieres E, Groome P, Kennedy C, Krasnik M, Peake M, Shemanski L, et al: The IASLC lung cancer staging project: External validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 12:1109–1121. 2017. View Article : Google Scholar : PubMed/NCBI
12	Fang C, Liu T, Liang W, Feng S, Su Z, Tang H, Huang H and Chen Z: Clinical pharmacist participation in selecting and dosing targeted drugs for a patient with ALK-positive non-small cell lung cancer: A case report. Ann Transl Med. 9:14882021. View Article : Google Scholar : PubMed/NCBI
13	Ma P, Huang R, Gu Y, Fang Y, Wu X, Chen DS, Zhang HW, Gao W and Shu Y: Savolitinib monotherapy exerted significant benefit in a non-small cell lung cancer patient with osimertinib resistance harboring primary EGFR L858R mutation and MET amplification: A case report. Anticancer Drugs. Aug 10–2022.(Epub ahead of print). View Article : Google Scholar
14	Lim JU: Overcoming osimertinib resistance in advanced non-small cell lung cancer. Clin Oncol (R Coll Radiol). 33:619–626. 2021. View Article : Google Scholar : PubMed/NCBI
15	Cui Q, Hu Y, Cui Q, Wu D, Mao Y, Ma D and Liu H: Osimertinib rechallenge with bevacizumab vs. chemotherapy plus bevacizumab in EGFR-Mutant NSCLC patients with osimertinib resistance. Front Pharmacol. 12:7467072021. View Article : Google Scholar : PubMed/NCBI
16	Satoh H and Kagohashi K: Response to erlotinib and bevacizumab combination therapy after acquired resistance to osimertinib in patients with non-small cell lung cancer. Anticancer Drugs. 33:320–322. 2022. View Article : Google Scholar : PubMed/NCBI
17	Lu S, Wang Q, Zhang G, Dong X, Yang CT, Song Y, Chang GC, Lu Y, Pan H, Chiu CH, et al: Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated post-national medical products administration approval results from the APOLLO registrational trial. J Thorac Oncol. 17:411–422. 2022. View Article : Google Scholar : PubMed/NCBI
18	Zhang Y, Zhang Y, Niu W, Ge X, Huang F, Pang J, Li X, Wang Y, Gao W, Fan F, et al: Experimental study of almonertinib crossing the blood-brain barrier in EGFR-Mutant NSCLC brain metastasis and spinal cord metastasis models. Front Pharmacol. 12:7500312021. View Article : Google Scholar : PubMed/NCBI
19	Yang F, Zhang W, Shang X, Liu N, Ma X, Qin J, Zhang Y, Liu Y and Wang X: Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis. Crit Rev Oncol Hematol. 177:1037602022. View Article : Google Scholar : PubMed/NCBI
20	Shen G, Shi L, Tian X, Huang D, Chen H, Gao C, Shen X and Zhang H: Case report: Response to almonertinib in a patient with metastatic NSCLC resistant to osimertinib due to acquired EGFR L718Q Mutation. Front Pharmacol. 12:7318952021. View Article : Google Scholar : PubMed/NCBI
21	Wu L, Zhong W, Li A, Qiu Z, Xie R, Shi H and Lu S: Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: A case report and literature review. Ann Transl Med. 9:9502021. View Article : Google Scholar : PubMed/NCBI
22	Zhang Q, Liu H and Yang J: Aumolertinib effectively reduces clinical symptoms of an EGFR L858R-Mutant non-small cell lung cancer case coupled with osimertinib-induced carditoxicity: Case report and review. Front Endocrinol. 13:8339292022. View Article : Google Scholar : PubMed/NCBI
23	Yang JC, Camidge DR, Yang CT, Zhou J, Guo R, Chiu CH, Chang GC, Shiah HS, Chen Y, Wang CC, et al: Safety, efficacy, and pharmacokinetics of almonertinib (HS-10296) in pretreated patients With EGFR-Mutated advanced NSCLC: A multicenter, open-label, phase 1 trial. J Thorac Oncol. 15:1907–1918. 2020. View Article : Google Scholar : PubMed/NCBI
24	Li Y, Meng L, Ma Y, Li Y, Xing X, Guo C and Dong Z: Determination of osimertinib, aumolertinib, and furmonertinib in human plasma for therapeutic drug monitoring by UPLC-MS/MS. Molecules. 27:44742022. View Article : Google Scholar : PubMed/NCBI
25	Deng Y, Yang C, Liu W, Cai S and Guo X: Aumolertinib-based comprehensive treatment for an uncommon site of EGFR exon 20 insertion mutations with multiple metastases non-small cell lung cancer: A case report. Anticancer Drugs. 33:406–412. 2022. View Article : Google Scholar : PubMed/NCBI
26	Yang GJ, Li J, Xu HY, Sun Y, Liu L, Li HS, Yang L, Zhang Y, Li GH and Wang Y: Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations. Lung Cancer. 152:39–48. 2021. View Article : Google Scholar : PubMed/NCBI